Inventiva/$IVA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Inventiva
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
Ticker
$IVA
Sector
Primary listing
Employees
73
Headquarters
Website
Inventiva Metrics
BasicAdvanced
$1.1bn
-
-$2.23
0.95
-
Price and volume
Market cap
$1.1bn
Beta
0.95
52-week high
$7.98
52-week low
$2.85
Average daily volume
398k
Financial strength
Current ratio
3.159
Quick ratio
1.408
Long term debt to equity
-696.238
Total debt to equity
-809.515
Interest coverage (TTM)
-0.66%
Profitability
EBITDA (TTM)
-156.168
Gross margin (TTM)
99.67%
Net profit margin (TTM)
-4,468.05%
Operating margin (TTM)
-1,965.46%
Effective tax rate (TTM)
-0.01%
Revenue per employee (TTM)
$106,070
Management effectiveness
Return on assets (TTM)
-45.08%
Return on equity (TTM)
523.99%
Valuation
Price to revenue (TTM)
107.381
Price to book
-30.83
Price to tangible book (TTM)
-30.63
Price to free cash flow (TTM)
-8.095
Free cash flow yield (TTM)
-12.35%
Free cash flow per share (TTM)
-0.663
Growth
Revenue change (TTM)
-52.03%
Earnings per share change (TTM)
-38.48%
3-year revenue growth (CAGR)
-27.92%
10-year revenue growth (CAGR)
-0.88%
3-year earnings per share growth (CAGR)
13.13%
10-year earnings per share growth (CAGR)
7.98%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Inventiva stock?
Inventiva (IVA) has a market cap of $1.1B as of May 11, 2026.
What is the P/E ratio for Inventiva stock?
The price to earnings (P/E) ratio for Inventiva (IVA) stock is 0 as of May 11, 2026.
Does Inventiva stock pay dividends?
No, Inventiva (IVA) stock does not pay dividends to its shareholders as of May 11, 2026.
When is the next Inventiva dividend payment date?
Inventiva (IVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Inventiva?
Inventiva (IVA) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.